Biomedical Engineering Reference
In-Depth Information
69. Perez O, Gay P, Franqueza L et al (1995) Electromechanical effects of zatebradine on isolated
guinea pig cardiac preparations. J Cardiovasc Pharmacol 26:46-54
70. Gargini C, Demontis GC, Bisti S et al (1999) Effects of blocking the hyperpolarization-
activated current (Ih) on the cat electroretinogram. Vis Res 39:1767-1774
71. Satoh TO, Yamada M (2002) Multiple inhibitory effects of zatebradine (UL-FS 49) on the
electrophysiological properties of retinal rod photoreceptors. Pflugers Arch 443:532-540
72. Cervetto L, Demontis GC, Gargini C (2007) Cellular mechanisms underlying the pharmaco-
logical induction of phosphenes. Br J Pharmacol 150:383-390
73. Schmitz-Spanke S, Granetzny A, Stoffels B et al (2004) Effects of a bradycardic agent on
postischemic cardiac recovery in rabbits. J Physiol Pharmacol 55:705-712
74. Simon L, Ghaleh B, Puybasset L et al (1995) Coronary and hemodynamic effects of S 16257,
a new bradycardic agent, in resting and exercising conscious dogs. J Pharmacol Exp Ther
275:659-666
75. Thollon C, Bidouard JP, Cambarrat C et al (1997) Stereospecific in vitro and in vivo effects of
the new sinus node inhibitor (+)-S 16257. Eur J Pharmacol 339:43-51
76. Bois P, Bescond J, Renaudon B et al (1996) Mode of action of bradycardic agent, S 16257, on
ionic currents of rabbit sinoatrial node cells. Br J Pharmacol 118:1051-1057
77. Bucchi A, Baruscotti M, DiFrancesco D (2002) Current-dependent block of rabbit sino-atrial
node I(f) channels by ivabradine. J Gen Physiol 120:1-13
78. Bucchi A, Tognati A, Milanesi R et al (2006) Properties of ivabradine-induced block of
HCN1 and HCN4 pacemaker channels. J Physiol 572:335-346
79. Thollon C, Bedut S, Villeneuve N et al (2007) Use-dependent inhibition of hHCN4 by
ivabradine and relationship with reduction in pacemaker activity. Br J Pharmacol 150:37-46
80. Monnet X, Ghaleh B, Colin P et al (2001) Effects of heart rate reduction with ivabradine on
exercise-induced myocardial ischemia and stunning. J Pharmacol Exp Ther 299:1133-1139
81. Vilaine JP, Bidouard JP, Lesage L et al (2003) Anti-ischemic effects of ivabradine, a selective
heart rate-reducing agent, in exercise-induced myocardial ischemia in pigs. J Cardiovasc
Pharmacol 42:688-696
82. Monnet X, Colin P, Ghaleh B et al (2004) Heart rate reduction during exercise-induced
myocardial ischaemia and stunning. Eur Heart J 25:579-586
83. Borer JS, Fox K, Jaillon P et al (2003) Ivabradine Investigators Group. Antianginal and
antiischemic effects of ivabradine, an I(f) inhibitor, in stable angina: a randomized, double-
blind, multicentered, placebo-controlled trial. Circulation 107:817-823
84. Tardif JC, Ford I, Tendera M et al (2005) INITIATIVE investigators. Efficacy of ivabradine, a
new selective I(f) inhibitor, compared with atenolol in patients with chronic stable angina.
Eur Heart J 26:2529-2536
85. Fox K, Ford I, Steg PG et al (2008) BEAUTIFUL investigators. Ivabradine for patients with
stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a
randomised, double-blind, placebo-controlled trial. Lancet 372:807-816
86. Fox K, Ford I, Steg PG et al (2008) BEAUTIFUL investigators. Heart rate as a prognostic risk
factor in patients with coronary artery disease and left-ventricular systolic dysfunction
(BEAUTIFUL): a subgroup analysis of a randomised controlled trial. Lancet 372:817-821
87. Bohm M, Swedberg K, Komajda M et al (2010) SHIFT investigators. Heart rate as a risk
factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a
randomised placebo-controlled trial. Lancet 376:886-894
88. Swedberg K, Komajda M, B
ohm M et al (2010) SHIFT investigators. Ivabradine and
outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet
376:875-885
89. Fernandez-Velasco M, Goren N, Benito G et al (2003) Regional distribution of hyperpolari-
zation-activated current (If) and hyperpolarization-activated cyclic nucleotide-gated channel
mRNA expression in ventricular cells from control and hypertrophied rat hearts. J Physiol
553:395-405
€
